Donepezil detailed information: Difference between revisions

Jump to navigation Jump to search
m (Protected "Donepezil detailed information": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
{{drugbox
{{drugbox
| IUPAC_name = 2-[(1-benzyl-4-piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1-one
| IUPAC_name = 2-[(1-benzyl-4-piperidyl)methyl]- 5,6-dimethoxy-2,3-dihydroinden-1-one
Line 20: Line 21:
| excretion = 0,11-0,13 (l/h/kg)
| excretion = 0,11-0,13 (l/h/kg)
}}
}}
{{SI}}
{{CMG}}
==Overview==
'''Donepezil''', marketed under the trade name '''Aricept''' ([[Eisai Co.|Eisai]]), is a centrally acting reversible [[cholinesterase|acetyl cholinesterase]] inhibitor. Its main therapeutic use is in the treatment of [[Alzheimer's disease]] where it is used to increase cortical [[acetylcholine]]. It has an [[oral bioavailability]] of 100% and easily crosses the [[blood-brain barrier]]. Because it has a [[half life]] of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks.
'''Donepezil''', marketed under the trade name '''Aricept''' ([[Eisai Co.|Eisai]]), is a centrally acting reversible [[cholinesterase|acetyl cholinesterase]] inhibitor. Its main therapeutic use is in the treatment of [[Alzheimer's disease]] where it is used to increase cortical [[acetylcholine]]. It has an [[oral bioavailability]] of 100% and easily crosses the [[blood-brain barrier]]. Because it has a [[half life]] of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks.



Latest revision as of 15:16, 23 October 2011

Donepezil detailed information
File:Donepezil skeletal.svg
Clinical data
Routes of
administration
Oral tablet, 5 & 10 mg
ATC code
Pharmacokinetic data
Bioavailability100 (%)
Protein binding96%
Elimination half-life70 hours
Excretion0,11-0,13 (l/h/kg)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC24H29NO3
Molar mass379.492 g/mol

WikiDoc Resources for Donepezil detailed information

Articles

Most recent articles on Donepezil detailed information

Most cited articles on Donepezil detailed information

Review articles on Donepezil detailed information

Articles on Donepezil detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Donepezil detailed information

Images of Donepezil detailed information

Photos of Donepezil detailed information

Podcasts & MP3s on Donepezil detailed information

Videos on Donepezil detailed information

Evidence Based Medicine

Cochrane Collaboration on Donepezil detailed information

Bandolier on Donepezil detailed information

TRIP on Donepezil detailed information

Clinical Trials

Ongoing Trials on Donepezil detailed information at Clinical Trials.gov

Trial results on Donepezil detailed information

Clinical Trials on Donepezil detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Donepezil detailed information

NICE Guidance on Donepezil detailed information

NHS PRODIGY Guidance

FDA on Donepezil detailed information

CDC on Donepezil detailed information

Books

Books on Donepezil detailed information

News

Donepezil detailed information in the news

Be alerted to news on Donepezil detailed information

News trends on Donepezil detailed information

Commentary

Blogs on Donepezil detailed information

Definitions

Definitions of Donepezil detailed information

Patient Resources / Community

Patient resources on Donepezil detailed information

Discussion groups on Donepezil detailed information

Patient Handouts on Donepezil detailed information

Directions to Hospitals Treating Donepezil detailed information

Risk calculators and risk factors for Donepezil detailed information

Healthcare Provider Resources

Symptoms of Donepezil detailed information

Causes & Risk Factors for Donepezil detailed information

Diagnostic studies for Donepezil detailed information

Treatment of Donepezil detailed information

Continuing Medical Education (CME)

CME Programs on Donepezil detailed information

International

Donepezil detailed information en Espanol

Donepezil detailed information en Francais

Business

Donepezil detailed information in the Marketplace

Patents on Donepezil detailed information

Experimental / Informatics

List of terms related to Donepezil detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Donepezil, marketed under the trade name Aricept (Eisai), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks.

Studies in Alzheimer's disease

Currently, there is no definitive proof that use of donepezil or other similar agents alters the course or progression of Alzheimer's disease. However, 6-12 month controlled studies have shown modest benefits in cognition and/or behavior. Pilot studies have reported that donepezil therapy may potentially have effects on markers of disease progression, such as hippocampal volume. Therefore, many neurologists, psychiatrists, and primary care physicians use donepezil in patients with Alzheimer's disease. In 2005, the UK National Institute for Clinical Excellence (NICE) withdrew its recommendation for use of the drug for mild-to-moderate AD, on the basis that there is no significant improvement in functional outcome; of quality of life or of behavioral symptoms. However, NICE revised its guidelines to suggest that donepezil be used in moderate stage patients for whom the evidence is strongest.[1]

While the drug is currently indicated for mild to moderate Alzheimer's, there is also evidence from 2 trials that it may be effective for moderate to severe disease. An example of this is a Karolinska Institute paper published in The Lancet in early 2006, which states that donepezil improves cognitive function even in patients with severe Alzheimer's disease symptoms. [2]

Combinations

Donepezil is sometimes used in combination with Memantine, a newer agent for Alzheimer's disease, as the response to both together is considered superior to donepezil alone. In moderate to severe Alzheimer's, a controlled clinical trial has shown that the addition of Memantine to stable donepezil therapy improves cognition, functioning and behavior.

Uses for other conditions

Donepezil has been tested in other cognitive disorders including Lewy body dementia and Vascular dementia, but it is not currently approved for these indications. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, and Down syndrome. A 3 year NIH trial in patients with mild cognitive impairment reported that donepezil was superior to placebo in delaying rate of progression to dementia during the initial 18 months of the study but this was not sustained at 36 months. In a secondary analyses, a subgroup of individuals with the Apolipoprotein E4 genotype showed sustained benefits with donepezil throughout the study. However at this time donepezil is not indicated for prevention of dementia.

Relationship to class and placebo

Donepezil is generally better tolerated than others in its class, simpler to use, and the agent with the most number of well controlled clinical trials. Common side effects include bradycardia, nausea, diarrhea, anorexia, abdominal pain, and vivid dreams. In 2006, Eisai, the manufacturer issued a statement that a single vascular dementia study found a difference in the percent of study participants who died in the donepezil group (1.7%) versus the placebo group (0%) and that this could be due to an unusually low death rate on the placebo group. An analysis of all three Vascular Dementia trials, according to Eisai, "shows no statistically significant differences in observed mortality rates between the donepezil and placebo groups (1.7% vs. 1.1%)".

Pilot study

In July 2002, a pilot study, reported that donepezil improves the memory of aging pilots. The researchers trained pilots in a flight simulator to perform specific maneuvers and to respond to emergencies that developed during their mock flight, after giving half the pilots donepezil and half a placebo. One month later they retested the pilots and found that those who had taken the donepezil remembered their training better, as shown by improved performance.[3] However, several other studies in normal older adults (before and after the above study) have not shown any significant cognitive improvements or shown inconsistent findings.[citation needed]

References

  1. Xiong G, Doraiswamy PM (2005). "Combination drug therapy for Alzheimer's disease: what is evidence-based, and what is not?". Geriatrics. 60 (6): 22–6. PMID 15948662.
  2. "Drug 'treats severe Alzheimer's'". Retrieved 2007-07-24.
  3. Yesavage JA, Mumenthaler MS, Taylor JL; et al. (2002). "Donepezil and flight simulator performance: effects on retention of complex skills". Neurology. 59 (1): 123–5. PMID 12105320.
  • Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4

External links

  • Official Aricept product site [2]

Template:Anticholinesterases Template:Anti-dementia drugs

de:Donepezil